<DOC>
	<DOCNO>NCT01316770</DOCNO>
	<brief_summary>Background : - Sj ( SqrRoot ) ( Delta ) gren syndrome autoimmune disease ( immune system attack normal body tissue ) affect salivary gland . Many people Sj ( SqrRoot ) ( Delta ) gren syndrome able make enough saliva salivary gland inflame . The dry mouth result interfere daily activity lead dental cavity , mouth sore , infection . Injections corticosteroid parotid gland improve saliva production people Sj ( SqrRoot ) ( Delta ) gren syndrome , current treatment practice may provide temporary relief . Researchers interested study effectiveness strong corticosteroid injection ( use dexamethasone ) determine corticosteroid treatment actually work . Objectives : - To evaluate effectiveness mechanic dexamethasone injection improve saliva production individual primary Sj ( SqrRoot ) ( Delta ) gren syndrome . Eligibility : - Women 18 great age diagnose primary Sj ( SqrRoot ) ( Delta ) gren syndrome , biopsy minor salivary gland past 5 year show moderate level inflammation . Design : - Participants screen full medical history physical examination , blood urine test , salivary gland biopsy . Participants also screen test saliva flow production evaluation salivary duct gland , complete questionnaire dry mouth symptom . - At first treatment visit , participant receive injection dexamethasone one parotid gland injection saline gland . After injection , participant provide blood sample test level dexamethasone blood . - Two week first treatment , participant return evaluation visit saliva flow rate measurement take , complete questionnaire dry mouth symptom . - Four week first treatment , participant second treatment parotid gland , test questionnaire . - Participants additional evaluation visit 6 8 week first treatment visit , followup telephone call approximately 6 week last dexamethasone treatment visit .</brief_summary>
	<brief_title>Dexamethasone Irrigation Parotid Glands Primary Sj ( SqrRoot ) ( Delta ) Gren Syndrome Subjects</brief_title>
	<detailed_description>BACKGROUND : Salivary gland dysfunction one major manifestation Sjogren syndrome ( SS ) . Although inflammation think play important role exocrinopathy , correlation glandular dysfunction inflammation limit . Systemic anti-inflammatory therapy test date , tumor necrosis factor antagonist , effective treatment SS salivary hypofunction , raise doubt inflammation sole cause salivary gland dysfunction . However , none trial test whether anti-inflammatory effect achieve glandular tissue . Studies Izumi et al found limit course low-dose topical corticosteroid apply parotid gland result sustained improvement saliva production . Unfortunately , study examine mechanistic effect corticosteroid major salivary gland . A plausible assumption corticosteroid improve salivary gland function reduce inflammation , although associate mechanism , improve transcellular ion transport epithelial cell rule . This study aim study efficacy low-dose topical corticosteroid ( dexamethasone ) irrigation parotid gland reduce salivary dysfunction subject SS , also evaluate effect treatment inflammation possible mechanistic process . PRIMARY OBJECTIVE : - To determine whether irrigation parotid gland low-dose topical dexamethasone improve parotid salivary gland flow SS subject . SECONDARY OBJECTIVES : - To perform mechanistic study determine mechanisms action low-dose topical corticosteroid irrigation parotid gland . - To assess biomarkers inflammation salivary gland dysfunction SS subject treat low-dose topical corticosteroid irrigation parotid gland . - To assess localized safety dexamethasone irrigation parotid gland , compare placebo . STUDY POPULATION : The study enroll 20 adult female primary SS order randomize treat 16 subject . Key enrollment criterion include focus score great equal 3 minor salivary gland biopsy previous 5 year measurable stimulate bilateral parotid salivary flow ( great equal 0.01 mL/min per gland ) . Subjects recruit protocol 84-D-0056 , conducted National Institutes Health ( NIH ) . DESIGN : This single-site , randomized-within-subject , double-blind , placebo-controlled , phase 2 pilot study subject receive active drug ( dexamethasone ) placebo ( normal saline ) , thereby act controls.The study design doubly-repeated measure ; within subject , measure repeat time treatment ( i.e. , one side mouth receive dexamethasone receives placebo. ) . After baseline assessment salivary flow measurement salivary function , subject randomly assign , double-blind fashion , dexamethasone irrigation one parotid gland normal saline irrigation parotid gland . They undergo total 2 treatment session , 4 week apart ( Days 0 28 ) . Post-treatment assessment salivary flow , dry mouth symptom , adverse event ( AEs ) perform specified interval . OUTCOME MEASURES : Primary Endpoint : - Change salivary flow Day 0 Day 56 . Secondary Endpoints : - Change focus score parotid biopsy Screening Day 56 . - Change salivary flow Day 0 study Days 14 , 28 , 42 , 56 . - Changes assessment Patient Dry Mouth Questionnaire Day 0 study Days 14 , 28 , 42 , 56 . - Changes assessment Sj ( SqrRoot ) ( Delta ) gren Disease Activity Index Day 0 study Days 14 , 28 , 42 , 56 . - Changes assessment salivary function baseline study Day 56 , include technetium scan salivary gland . - Changes laboratory measure inflammation . - Frequency AEs related treatment ; AE location ( body site , right left ) , record evaluate , applicable . Exploratory endpoint - Changes mechanistic endpoint baseline study Days 14 , 28 , 42 , 56 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA : Female gender age 18 great . Diagnosed primary SS Protocol 84D0056 . Stimulated salivary flow least 0.01 mL/min parotid gland , use standard operating procedure ( SOP ) National Institute Dental Craniofacial Research ( NIDCR ) Molecular Physiology Therapeutics Branch ( MPTB ) Sjogren Syndrome Clinic Minor salivary gland biopsy focus score great equal 1 obtain 0 7 year prior study enrollment . Biopsies outside National Institutes Health ( NIH ) must review NIH Pathology Department . An MSG biopsy require following situation : The last biopsy obtain use rituximab . The last biopsy obtain use immunosuppressant , biologics , diseasemodifying antirheumatic drug 3 month . The last biopsy obtain use systemic corticosteroid ( 2 week short period dose 0.5 mg/kg ) local parotid corticosteroid . The use topical intraarticular/periarticular corticosteroid require repeat biopsy . For woman childbearing potential , use , willingness use , effective method birth control study . Effective method include abstinence , history hysterectomy , tubal ligation , intrauterine device , license hormonal method , condom , diaphragm , cervical cap . Ability provide write informed consent prior entry study . EXCLUSION CRITERIA : History lymphoma . History mycosis , aspergillosis , deep fungal infection parotid gland . History salivary gland malignancy ( primary metastatic salivary gland ) . History secondary Sj ( SqrRoot ) ( Delta ) gren syndrome . Parotid infection resolve least 4 week start Screening Period . Any active viral infection resolve start Screening Period . Pregnancy lactation . Use biologics within 3 month start Screening Period . Any experimental therapy within 3 month start Screening Period . Use immunosuppressant methotrexate , leflunomide , azathioprine , cyclophosphamide , systemic cyclosporine , systemic corticosteroid within 3 month prior start Screening Period . Use inhale corticosteroid within 3 month prior start Screening Period . Use antimalarial regular use NSAIDs unless dose stable ( decrease ) least 2 month . Inability discontinue use saliva stimulant pilocarpine cevimeline 24 hour study visit . Parotid intraductal irrigation instillation steroid within past year . Use rituximab within 6 month prior start Screening Period . Allergy steroid technetium , component formulation . Current use warfarin heparin . History bleed disorder . Both severe atrophy fibrosis MSG note pathology report MSG biopsy . Inability comply protocol procedure number require visit . Inability cannulate one parotid gland . Parotid fill volume le 0.5 mL one parotid gland . Significant concurrent medical condition circumstance , opinion principal investigator , could affect subject ability tolerate complete study . Unable understand write English completion study questionnaire .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 13, 2016</verification_date>
	<keyword>Xerostomia</keyword>
	<keyword>Sj ( SqrRoot ) ( Delta ) gren Syndrome</keyword>
	<keyword>Interventional Study</keyword>
	<keyword>Sjogren Syndrome</keyword>
	<keyword>Dry Mouth</keyword>
</DOC>